After re listening to the CME Aug video from Stehen Nicholls,  I could not  help but notice some enthusiam in DR Stephen Nicholls tone as he spoke during the video about the potential for apabetalone and the future of epigenetics

https://pace-cme.org/2017/08/30/managing-diabetes-cvd-is-epigenetics-a-new-way-forward/

I also noticed that Dr Stephen Nicholls some credentials and affilitations in bold, I wonder if some large BP may now take notice of RVX 208 and may want a piece of it !!!

Dr. Nicholls has received research grants from Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, Roche, Resverlogix, Novartis, Amgen, LipoScience, Sanofi-Regeneron, and The Medicines Company; is on the Speakers Bureau of AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; and is a consultant for and on the advisory board of AstraZeneca, Abbott, AtheroNova, Esperion, Amgen, Novartis, Omthera, CSL Behring, Boehringer Ingelheim, Pfizer, Merck Schering-Plough, Takeda, Roche, Novo Nordisk, LipoScience, and Anthera. Dr. Nissen has received research grants from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and Eli Lilly; and is a consultant for and on the advisory board of many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.